Article
Immunology
Shushu Zhao, Shuting Wu, Sheng Jiang, Gan Zhao, Bin Wang
Summary: This study aimed to develop an effective cancer vaccine using inactivated tumor cells and evaluate its tumor protection potential. The results showed that immunization with inactivated CMS5 cells improved tumor suppression in the CMS5 tumor model, but had no effect on the E.G7 tumor model. Dendritic cell responses to tumor antigens were critical, and the combination of inactivated tumor cells with anti-CD25 antibodies showed increased tumor prevention efficacy.
Article
Immunology
Chongming Jiang, Jianrong Li, Wei Zhang, Zhenkun Zhuang, Geng Liu, Wei Hong, Bo Li, Xiuqing Zhang, Cheng-Chi Chao
Summary: This study constructed a database of peptide-based cancer vaccines, which showed that modified peptides derived from artificially modified proteins are suitable for cancer vaccines, screening for HLA class II affinity peptides may be an effective therapeutic strategy, and Montanide ISA-51 might be an effective adjuvant. A machine learning model was also built to assist in designing peptide-based cancer vaccines with high clinical responses.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Peter D. Katsikis, Ken J. Ishii, Christopher Schliehe
Summary: The recent success of cancer immunotherapies has drawn attention to the potential of using the immune system for cancer treatment. Personalized neoantigen vaccines have the ability to boost the immune response against specific cancer antigens. However, there are challenges that need to be overcome, such as neoantigen selection, adjuvants, and the immunosuppressive tumor microenvironment.
NATURE REVIEWS IMMUNOLOGY
(2023)
Review
Oncology
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen, Daichao Wu
Summary: This article provides a comprehensive overview of therapeutic cancer vaccines, including their classification, clinical application, efficacy, and combination strategies with other therapies. It offers a valuable theoretical basis for the future clinical application and development of therapeutic cancer vaccines.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Editorial Material
Medicine, General & Internal
Eric J. Rubin, Lindsey R. Baden, Kathleen M. Neuzil, Stephen Morrissey
Summary: The interview discussed the future development of vaccines against Covid-19 and other infectious diseases.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Brandon Mistretta, Sakuni Rankothgedera, Micah Castillo, Mitchell Rao, Kimberly Holloway, Anjana Bhardwaj, Maha El Noafal, Constance Albarracin, Randa El-Zein, Hengameh Rezaei, Xiaoping Su, Rehan Akbani, Xiaoshan M. Shao, Brian J. Czerniecki, Rachel Karchin, Isabelle Bedrosian, Preethi H. Gunaratne
Summary: This study presents a strategy to identify immunogenic neoantigen candidates from unique amino acid sequences at the junctions of fusion proteins, and suggests a potential vaccine strategy for the treatment of breast cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Oncology
John T. Schiller, Douglas R. Lowy
Summary: Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, this article revisits the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and provide insights into the clinical development progress and challenges that need to be overcome for wide implementation.
Review
Immunology
Ahmed Elkashif, Marwa Alhashimi, Ekramy E. Sayedahmed, Suryaprakash Sambhara, Suresh K. Mittal
Summary: The development of new vaccine strategies is urgently needed to address the challenges posed by the emergence of new viruses due to global population growth and environmental changes. Adenovirus-based vaccine platforms offer a promising solution to meet the broad immune needs in pandemic situations.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Hongxia Zhang, Xiaojun Xia
Summary: mRNA-based cancer vaccines are a popular approach for developing personalized and effective antitumor immunotherapy, delivering tumor antigen-encoding mRNA into dendritic cells for antigen presentation and stimulating innate immune response as an adjuvant effect. A minimalist nanovaccine formulation called C1 has shown significant antitumor efficacy on tumor mouse models, highlighting the potential of mRNA vaccines targeting the immunosuppressive tumor microenvironment.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Biochemistry & Molecular Biology
Laura Cuy-Chaparro, Cesar Reyes, Eliana Vanessa Diaz-Guiot, Darwin Andres Moreno-Perez, Manuel Alfonso Patarroyo
Summary: Bovine babesiosis is a significant tick-borne disease caused by Babesia parasites. Babesia bovis is the most severe species associated with the disease, leading to high economic losses. The traditional approach of using live attenuated vaccines against B. bovis has limitations, prompting researchers to explore alternative methodologies for vaccine production.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Materials Science, Multidisciplinary
Jianqin Yan, Hongli Yu, Xiaowen Tang, Fashun Li, Zhipeng Li, Yan Liang, Bin He, Xianwen Wang, Yong Sun
Summary: Chemotherapy can convert tumor cells into tumor vaccines, but the resulting antitumor immunity is weak. This study presents a novel strategy using targeted tetrahedral DNA nanostructures modified by AS1411 and immune adjuvant CpG to achieve a multi-drug co-loading system, resulting in a strong immunogenic effect. The combination of chemo-photo-immune therapy effectively inhibited tumor growth by activating T cells and improving immunosuppression.
MATERIALS & DESIGN
(2023)
Review
Oncology
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J. M. Melief, Nina Bhardwaj
Summary: Therapeutic cancer vaccines aim to induce tumor regression, eradicate minimal residual disease, establish lasting anti-tumor memory, and avoid non-specific or adverse reactions. However, challenges arise due to tumor-induced immunosuppression and immunoresistance, hindering the achievement of these goals.
NATURE REVIEWS CANCER
(2021)
Review
Immunology
Giuseppe Cappellano, Hugo Abreu, Chiara Casale, Umberto Dianzani, Annalisa Chiocchetti
Summary: The development of vaccines has evolved from being based on live-attenuated or inactivated pathogens to next-generation nano/microparticle-based vaccines. These new vaccines can induce a more potent CD8(+) T-cell response and serve as ideal carriers for proteins, adjuvants, and nucleic acids.
Article
Materials Science, Multidisciplinary
Shengxian Li, Jing Wu, Xiaoping Li, Jingtao Chen, Chunxi Wang
Summary: Cancer vaccines are a promising strategy for preventing cancer progression through activating antitumor immunity. However, their clinical application is limited by systemic toxicity and low immunogenicity. To overcome these limitations, researchers are exploring the use of biomaterials as immune adjuvants in cancer vaccines to enhance immunogenicity and antigen presentation.
MATERIALS & DESIGN
(2022)
Review
Pharmacology & Pharmacy
Shruthi Polla Ravi, Yasmeen Shamiya, Aishik Chakraborty, Cynthia Elias, Arghya Paul
Summary: Vaccines have been essential in training the immune system, but face challenges in manufacturing, large-scale production, and storage, with some showing suboptimal immunogenicity. A new class of biomimetic materials has emerged as an alternative vaccination strategy.
TRENDS IN PHARMACOLOGICAL SCIENCES
(2021)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)